West Cancer Center’s Molecular Tumor Board, one of the first in the nation, reviews patients diagnosed with metastatic cancer who qualify to have a tumor biopsy for extensive molecular testing. This process includes the evaluation of protein expression, genetic amplification, and sequencing of genes commonly associated with cancer. This board of oncologists, researchers, pathologists, and geneticists collaborate to understand not only the genomic information of tumors but also how to interpret that information so that it can be applied in clinical practice.
We continue to further our understanding of genomics and how to use that information to improve patient outcomes. For the cases that our team is unable to provide treatment recommendations, we use this as an opportunity to conduct more research on the specific tumor abnormalities, so that we will be able to provide recommendations in the future. Recommendations may include consideration for an available clinical trial, treatment with an approved anti-cancer drug, and genetic counseling and testing for cancer syndromes.